Candid Therapeutics Overview
- Year Founded
-
2024
- Status
-
Acquired/Merged
- Employees
-
42
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.2B
Candid Therapeutics General Information
Description
Operator of a biotechnology research company designed to create novel, easy-to-administer therapies for autoimmune diseases. The company offers advanced T-cell engager antibodies, precisely redirecting T-cells to selectively eliminate autoreactive B-cells, enabling patients with autoimmune diseases to experience transformative efficacy and improved therapeutic outcomes.
Contact Information
Website
www.candidrx.com(Operating Subsidiary)
Corporate Office
- 11622 El Camino Real
- Suite 150
- San Diego, CA 92130
- United States
Corporate Office
- 11622 El Camino Real
- Suite 150
- San Diego, CA 92130
- United States
Candid Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 01-Mar-2026 | $2.2B | Completed | Clinical Trials - Phase 1 | ||
| 5. PIPE | 09-Mar-2026 | Cancelled | Clinical Trials - Phase 1 | |||
| 4. Reverse Merger | 02-Mar-2026 | Cancelled | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 20-Aug-2024 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 18-Jul-2024 | $164M | $164M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
Candid Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 105,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 18.33% |
Candid Therapeutics Patents
Candid Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165008-A1 | Compositions and methods of use of multispecific antibodies | Pending | 29-Jan-2025 | ||
| WO-2026161569-A2 | Compositions and methods of use of multispecific antibodies | Pending | 24-Jan-2025 | ||
| WO-2026161569-A3 | Compositions and methods of use of multispecific antibodies | Pending | 24-Jan-2025 | ||
| WO-2026161360-A1 | Compositions of multispecific antibodies and methods of use thereof | Pending | 21-Jan-2025 | ||
| WO-2026136426-A1 | Compositions and methods of use of antibodies targeting cd20 and cd3 | Pending | 18-Dec-2024 | A61P37/06 |
Candid Therapeutics Signals
Candid Therapeutics Former Investors (28)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boxer Capital | Corporate Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Fairmount Partners | Investment Bank | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
Candid Therapeutics Investments & Acquisitions (3)
Candid Therapeutics’s most recent deal was a Corporate Asset Purchase with WuXi Biologics (Preclinical Trispecific T-cell Engager in Wuxi, China). The deal was made on 06-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| WuXi Biologics (Preclinical Trispecific T-cell Engager in Wuxi, China) | 06-Jan-2025 | Corporate Asset Purchase | Buildings and Property | ||
| TRC 2004 | 09-Sep-2024 | Merger/Acquisition | Drug Discovery | ||
| Vignette Bio | 19-Aug-2024 | Merger/Acquisition | Drug Discovery |
Candid Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vignette Bio | San Diego, CA | 2023 | |
| TRC 2004 | San Diego, CA | 2020 |
Candid Therapeutics FAQs
-
When was Candid Therapeutics founded?
Candid Therapeutics was founded in 2024.
-
Where is Candid Therapeutics headquartered?
Candid Therapeutics is headquartered in San Diego, CA.
-
What is the size of Candid Therapeutics?
Candid Therapeutics has 42 total employees.
-
What industry is Candid Therapeutics in?
Candid Therapeutics’s primary industry is Drug Discovery.
-
Is Candid Therapeutics a private or public company?
Candid Therapeutics is a Private company.
-
What is the current valuation of Candid Therapeutics?
The current valuation of Candid Therapeutics is .
-
What is Candid Therapeutics’s current revenue?
The current revenue for Candid Therapeutics is .
-
How much funding has Candid Therapeutics raised over time?
Candid Therapeutics has raised $370M.
-
Who are Candid Therapeutics’s investors?
Boxer Capital, Cormorant Asset Management, Fairmount Partners, Fidelity Management & Research Company, and Foresite Capital are 5 of 28 investors who have invested in Candid Therapeutics.
-
When was Candid Therapeutics acquired?
Candid Therapeutics was acquired on 01-Mar-2026.
-
Who acquired Candid Therapeutics?
Candid Therapeutics was acquired by UCB.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process